The use of recombinant activated factor VII in platelet-associated bleeding

References

• Jurlander B, Thim L, Klausen NK et al. Recombinant activated factor VII (rFVIIa): characterization, manufacturing and clinical development. Semin Thromb Hemost 2001; 27: 373–383.
   PubMed Web of Science ®Google Scholar
• Hedner U, Erhardtsen E. Potential role for rFVIIa in transfusion medicine. Transfusion 2002; 42: 114–124.
   PubMed Web of Science ®Google Scholar
• Uhlmann EJ, Eby CS. Recombinant activated factor VIII for non-hemophiliac bleeding patients. Curr Opin Hematol 2004; 11: 198–204.
   PubMed Web of Science ®Google Scholar
• Franchini M, Zaffanello M, Veneri D. Recombinant factor VIIa. An update on its clinical use. Thromb Haemost 2005; 93: 1027–1035.
   PubMed Web of Science ®Google Scholar
• Kessler CM. New products for managing inhibitors to coagulationfactors: a focus on recombinant factor VIIa concentrate. Curr Opin Hematol 2000; 7: 408–413.
   PubMed Web of Science ®Google Scholar
• Ghorashian S, Hunt BJ. 'Off-license' use of recombinant activatedfactor VII. Blood Rev 2004; 18: 245–259.
   PubMed Web of Science ®Google Scholar
• Mathew P. The use of rFVIIa in non-haemophilia bleeding conditions in paediatrics. Thromb Haemost 2004; 92: 738–746.
   PubMed Web of Science ®Google Scholar
• Lisman T, De Groot PG. Mechanism of action of recombinant factor VIIa. J Thromb Haemost 2003; 1: 1138–1139.
   PubMed Web of Science ®Google Scholar
• Laurian Y. Treatment of bleeding in patients with platelet disorders: is there a place for recombinant factor VIIa? Pathophysiol Haemost Thromb 2002; 32: 37–40
   PubMed Web of Science ®Google Scholar
• Nurden AT. Inherited abnormalities of platelets. Thromb Haemost 1999; 82: 468–480.
   PubMed Web of Science ®Google Scholar
• Tengborn L, Petruson B. A patient with Glanzmann thrombasthe-nia and epistaxis successfully treated with recombinant factor VIIa. Thromb Haemost 1996; 75: 981–982.
   PubMed Web of Science ®Google Scholar
• Chuansumrit A, Sangkapreecha C, Hathirat P. Successful epistaxis control in a patient with Glanzmann thrombasthenia by increased bolus injection dose of recombinant factor VIIa. Thromb Haemost 1999; 82: 1778.
   PubMed Web of Science ®Google Scholar
• Poon MC, Demers C, Jobin F, Wu JW. Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia. Blood 1999; 94: 3951–3953.
   PubMed Web of Science ®Google Scholar
• Poon MC, D'Oiron R. Recombinant activated factor VII (NovoSeven) treatment of platelet-related bleeding disorders. International Registry on Recombinant Factor VIIa and Congenital Platelet Disorders Group. Blood Coagul Fibrinolysis 2000; 11 (Suppl. 1): S55–S68.
   PubMedGoogle Scholar
• Poon MC, D'Oiron R, Hann I et al. Use of recombinant factor VIIa (NovoSeven) in patients with Glanzmann thrombasthenia. Semin Hematol 2001; 38: 21–25.
   PubMed Web of Science ®Google Scholar
• Poon MC, D'Oiron R, Von Depka M, et al. Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey. J Thromb Haemost 2004; 2: 1096–1103.
   PubMed Web of Science ®Google Scholar
• Caglar K, Cetinkaya A, Aytac S, Gumruk F, Gurgey A. Use of recombinant factor VIIa for bleeding in children with Glanzmann thrombasthenia. Pediatr Hematol Oncol 2003; 20: 435–438.
   PubMed Web of Science ®Google Scholar
• Chuansumrit A. Confirmation of high dose recombinant factor VIIa in treating patients with Glanzmann thrombasthenia. J Thromb Haemost 2003; 1: 396.
   PubMed Web of Science ®Google Scholar
• Chuansumrit A, Suwannuraks M, Sri-Udomporn N, Pongtanakul B, Worapongpaiboon S. Recombinant activated factor VII combined with local measures in preventing bleeding from invasive dental procedures in patients with Glanzmann thrombasthenia. Blood Coagul Fibrinolysis 2003; 14: 187–190.
   PubMed Web of Science ®Google Scholar
• Almeida A, Khair K, Hann I, Liesner R. The use of recombinant factor VIIa in children with inherited platelet function disorders. Br J Haematol 2003; 121: 477–481.
   PubMed Web of Science ®Google Scholar
• D'Oiron R, Menart C, Trzeciak MC et al. Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann's thromboasthenia undergoing invasive procedures. Thromb Haemost 2000; 83: 644–647.
   PubMed Web of Science ®Google Scholar
• Valentino LA. Use of rFVIIa in 4 children with Glanzmann Thromboasthenia. J Pediatr Hematol Oncol 2004; 28: 653–658.
   Web of Science ®Google Scholar
• Peters M, Heijboer H. Treatment of a patient with Bernard-Soulier syndrome and recurrent nosebleeds with recombinant factor VIIa. Thromb Haemost 1998; 80: 352.
   PubMed Web of Science ®Google Scholar
• Fressinaud E, Sigaud-Fiks M, Le Boterff C, Piot B. Use of recombinant factor VIIa (NovoSeven®) for dental extraction in a patient affected by platelet-type (pseudo-) von Willebrand disease. Haemophilia 1998; 4: 299.
   Google Scholar
• Poon MC. Management of thrombocytopenic bleeding: is there a role for recombinant coagulation factor VIIa? Curr Hematol Rep 2003; 2: 139–147.
   PubMedGoogle Scholar
• Goodnough LT. Experiences with recombinant human factor VIIa in patients with thrombocytopenia. Semin Hematol 2004; 41 (Suppl. 1): S25–S29.
   Web of Science ®Google Scholar
• Culic S. Recombinant factor VIIa for refractive haemorrhage in autoimmune idiopathic thrombocytopenic purpura. Br J Haematol 2003; 120: 909–910.
   PubMed Web of Science ®Google Scholar
• Wrobel G, Dobaczewski G, Patkowski D, Sokol A, Grotthus E. Experiences with recombinant activated factor VII in the treatment of severe refractory thrombocytopenia. Pediatr Blood Cancer 2006; 47: 729–730.
   PubMed Web of Science ®Google Scholar
• Kristensen J, Killander A, Hippe E et al. Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. Haemostasis 1996; 26 (Suppl. 1): S159–S164.
   Google Scholar
• Blatt J, Gold SH, Wiley JM, Monahan PE, Cooper HC, Harvey D. Off-label use of recombinant factor VIIa in patients following bone marrow transplantation. Bone Marrow Transplant 2001; 28: 405–407.
   PubMed Web of Science ®Google Scholar
• de Fabritiis P, Dentamaro T, Picardi A, Cudillo R, Masi M, Amadori S. Recombinant factor VIIa for the management of severe hemorrhages in patients with hematologic malignancies. Haematologica 2004; 89: 243–245.
   PubMed Web of Science ®Google Scholar
• Hicks K, Peng D, Gajewski JL. Treatment of diffuse alveolar hemorrhage after allogeneic bone marrow transplant with recombinant factor VIIa. Bone Marrow Transplant 2002; 30: 975–978.
   PubMed Web of Science ®Google Scholar
• Vidarsson B, Onundarson PT. Recombinant factor VIIa for bleeding in refractory thrombocytopenia. Thromb Haemost 2000; 83: 634–635.
   PubMed Web of Science ®Google Scholar
• Gerotziafas GT, Zervas C, Gavrielidis G et al. Effective hemostasis with rFVIIa treatment in two patients with severe thrombocyto-penia and life-threatening hemorrhage. Am J Hematol 2002; 69: 219–222
   PubMed Web of Science ®Google Scholar
• Brenner B, Hoffman R, Balashov D, Shutluko E, Culic SD, Nizamoutdinova E. Control of bleeding caused by thrombocyto-penia associated with hematologic malignancy: an audit of the clinical use of recombinant activated factor VII. Clin Appl Thromb Hemost 2005; 11: 401–410.
   PubMed Web of Science ®Google Scholar
• Mantzios G, Tsirigotis P, Pappa V et al. Massive pulmonary embolism after treatment with rFVIIa in a thrombocytopenic patient with acute myelogenous leukemia and intractable bleeding. Eur J Haematol 2007; 78: 173–174.
   PubMed Web of Science ®Google Scholar
• Savani BN, Dunbar CE, Rick ME. Combination therapy with rFVIIa and platelets for hemorrhage in patients with severe thrombocytopenia and alloimmunization. Am J Hematol 2006; 81: 218–219.
   PubMed Web of Science ®Google Scholar
• Revesz T, Arets B, Bierings M, van den Bos C, Duval E. Recombinant factor VIIa in severe uremic bleeding. Thromb Haemost 1998; 80: 353.
   PubMed Web of Science ®Google Scholar
• Moisescu E, Ardelean L, Simion I, Muresan A, Ciupan R. Recombinant factor VIIa treatment of bleeding associated with acute renal failure. Blood Coagul Fibrinolysis 2000; 11: 575–577.
   PubMed Web of Science ®Google Scholar
• Stepinska J, Banaszewski M, Konopka A, Szajewski T. Activated recombinant factor VII (rFVIIa) in bleeding management after therapy with IIb/IIIa-inhibitor tirofiban. Thromb Haemost 2002; 87: 355–356.
   PubMed Web of Science ®Google Scholar